Tenaya (TNYA) CMO Tingley Whittemore Receives Awards

What Happened

• Tingley Whittemore, Chief Medical Officer of Tenaya Therapeutics (TNYA), was granted equity awards on 2026-09-10: 49,000 restricted stock units (RSUs) and a derivative award covering 293,000 shares (stock option style grant). Both grants show acquisition at $0 (typical for compensation awards) and were filed on Form 4 on 2026-09-11.

Key Details

• Transaction date: September 10, 2026; filing date: September 11, 2026 (appears timely).
• Consideration/price: $0 (grant/award).
• Vesting for RSUs (per footnote): 1/8 of the RSU award vests on February 15, 2027, then 1/8 every six months thereafter until fully vested.
• Vesting for the option-style award (per footnote): vests 1/48th monthly, beginning one month after the grant date.
• Grants made under the Tenaya Therapeutics, Inc. Amended and Restated 2021 Equity Incentive Plan.
• Footnote: filing notes 142,076 shares will be issued upon vesting of certain RSUs (this is part of the ownership/award disclosures in the filing).
• Shares owned after the transaction are not detailed in the excerpt provided.

Context

• RSUs convert to actual shares only upon vesting; they are not immediate open‑market purchases and generally reflect compensation incentives rather than direct market bets. The derivative award appears to be an option-style grant with monthly vesting; exercise (and any sale) would be a later, separate transaction. No sales or purchases (open‑market trades) by the insider were reported in this filing.